Old Web
English
Sign In
Acemap
>
Paper
>
Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximab
Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximab
2019
Lucia Y. Chen
Raakhee Shah
Kate Cwynarski
Jonathan Lambert
Christopher McNamara
Sajir Mohamedbhai
Andres Virchis
W Townsend
Shirley DSa
Kirit M. Ardeshna
Keywords:
Ofatumumab
Lymphoma
Diabetes mellitus
Immunology
Infusion related reaction
Rituximab
CD20
Medicine
Monoclonal antibody
in patient
anti cd20
Correction
Source
Cite
Save
Machine Reading By IdeaReader
7
References
6
Citations
NaN
KQI
[]